BOSTON, June 19, 2017 /PRNewswire/ -- Attendees of FierceBiotech's 2nd Annual Drug Development Forumwill obtain essential funding strategies and more productive R&D through executive-level networking opportunities. Convening at the Renaissance Boston Waterfront Hotel September 25–27, 2017, the conference draws together the industry's top decision
"Our primary objective behind this conference is to build a program for the industry, by the industry and we've been working very closely with our advisory board, our readers, and key industry leaders to develop a program that digs into the real issues facing our industry," said Rebecca Willumson, VP and Publisher of FierceBiotech.
Some sample sessions include:
Meet Increasing Demands for Real-World Evidence Donald Bergstrom, CMO, MERSANA THERAPEUTICS
Shorten the Path From Preclinical to Clinical PhasesJohn Hohneker, Executive Vice President, Head of R&D, FORMA THERAPEUTICS Sara Nochur, Senior Vice President, Regulatory Affairs, ALNYLAM PHARMACEUTICALS Richard Gregory, CSO, IMMUNOGENTimothy Lowinger, CSO, MERSANA THERAPEUTICS
Enable Flexibility, Creativity and Independence in Partnerships Between Large and Small Biotech CompaniesMichael Bailey, CEO, AVEO ONCOLOGYChandra Ramanathan, Vice President and Head, East Coast Innovation Center, BAYERCynthia Schwalm, President, North American Commercial Operations, IPSENRich Murray, CEO, JOUNCE THERAPEUTICS
Add Orphan Indications to Accelerate DevelopmentKrishna Menon, CSO, CELLCEUTIXJohn Lee, CMO, PHASEBIO PHARMACEUTICALS
How to Succeed in Novel Deal Structures (Even If They're Trying)Richard Brudnick, Executive Vice President, Business Development, BIOVERATIV Michael Aberman, Vice President, Strategy and Investor Relations, REGENERON Lindsay Rosenwald, CEO, FORTRESS BIOTECH
ABOUT FIERCEBIOTECHFierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. www.fiercebiotech.com
ABOUT EXL EVENTSExL Events, a division of Questex, LLC, is the industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe, Latin America and additional markets. www.exlevents.com
CONTACTFor information on exhibiting and sponsorship opportunities, please contact Andrew Sinetar at 212-400-6237 or firstname.lastname@example.org.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fiercebiotechs-drug-development-forum-attracts-executive-level-biopharma-professionals-for-second-annual-conference-in-boston-this-september-300475241.html
SOURCE ExL Events, LLC
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All